Company Overview and News

Eduspec jumps 14.29% on tie-up with KidZania owner fo STEM initiatives

2018-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): Eduspec Holdings Bhd jumped 14.29% this morning after it teamed up with KidZania owner and operator Rakan Riang Sdn Bhd to provide Science, Technology, Engineering and Mathematics (STEM) related initiatives.

KLCI seen trending sideways, to remain in consolidation mode

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI is seen trending sideways today and hover around the 1,800-point level, in line with the overnight rally at most global markets.
1562 6888 5187 0180 0107 AXXTF GLOCF

Axiata, HB Global, Glomac, BToto, Eduspec, PanPages, Kim Teck Cheong and Salcon

2018-09-19 theedgemarkets
KUALA LUMPUR (Sep 19): Based on corporate announcements and news flow today, stocks in focus for Thursday (Sep 20) may include the following: Axiata Group Bhd, HB Global Ltd, Glomac Bhd, Berjaya Sports Toto Bhd, Eduspec Holdings Bhd, PanPages Bhd, Kim Teck Cheong Consolidated Bhd and Salcon Bhd.
1562 6888 5187 0180 0107 AXXTF GLOCF

Eduspec partners KidZania operator to provide STEM-related activities

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): Eduspec Holdings Bhd is teaming up with KidZania owner and operator Rakan Riang Sdn Bhd to provide Science, Technology, Engineering and Mathematics (STEM) related initiatives.

Eduspec to raise up to RM6.9m via private placement

2018-09-07 theedgemarkets
KUALA LUMPUR: Eduspec Holdings Bhd has proposed to raise up to RM6.92 million via private placement to third-party investors to be identified later.
0107 BSMAF 1818

Eduspec proposes private placement

In a filing with Bursa Malaysia yesterday, the integrated education services provider said the proceeds raised would be used to repay bank borrowings and for working capital purposes.
0107 BSMAF 1818

KLCI seen under pressure, to track global markets

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI seen under pressure today, in line with the overnight decline at most global markets.
0154 5347 5115 0145 9296 TNABY 0107 TNABF 7123

Priceworth, TFP Solutions, TNB, FGV, Alam Maritim, MMC Corp, iDimension, Eduspec, RCE Capital and EA Holdings

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 6): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Sept 7) may include the following: Priceworth International Bhd, TFP Solutions Bhd, Tenaga Nasional Bhd, FGV Holdings Bhd, Alam Maritim Resources Bhd, MMC Corp Bhd, iDimension Consolidated Bhd, Eduspec Holdings Bhd, RCE Capital Bhd and EA Holdings Bhd.
0154 5347 5115 0145 9296 TNABY 0107 RCL TNABF BSMAF 7123 1818

Bursa Malaysia ends lower

2018-06-26 malaymail
KUALA LUMPUR, June 26 — Bursa Malaysia ended lower today after a slightly choppy trading session with buying interspersed with selling in bluechip counters, amid external negative sentiment.
PBLOF 0107 1295 BSMAF 1818

Stocks on a high

AS expected, the stock market had a relatively wild ride on Monday, its first day of business following the momentous 14th General Election (GE14).
7293 0035 3026 7889 0107 BATS 4162 BSMAF 1481 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...